The drug falls in the cardiovascular segment and the combined sales of all the strengths as per NDC was estimated at $301 million in 2007.
This marks the 38th abbreviated new drug application approval (ANDA) for the group. So far, the group has filed 78 ANDAs and 59 drug master files.